Ipraflo DPI Capsule is a combination bronchodilator containing Levosalbutamol 100 mcg and Ipratropium 40 mcg, formulated for the management of chronic obstructive pulmonary disease (COPD) and asthma. Levosalbutamol, a selective β2-adrenergic receptor agonist, provides rapid bronchodilation by relaxing the smooth muscles of the airways, thereby improving airflow and reducing bronchospasm. Ipratropium, an anticholinergic agent, complements this effect by inhibiting muscarinic receptors in the bronchial smooth muscle, leading to sustained bronchodilation and decreased mucus secretion. The dry powder inhaler (DPI) delivery system ensures efficient pulmonary deposition and rapid onset of action, enhancing patient compliance and therapeutic outcomes. Ipraflo DPI Capsule is indicated for the relief and prevention of bronchospasm in patients with obstructive airway diseases, including COPD and asthma, particularly in cases where monotherapy with either agent is insufficient. It is recommended to be used under medical supervision, with dosage tailored according to the severity of symptoms and patient response. Common adverse effects may include dry mouth, tremors, headache, and palpitations. Caution is advised in patients with cardiovascular disorders, glaucoma, and prostatic hypertrophy. Regular monitoring and adherence to prescribed dosage are essential for optimal efficacy and safety.